Home › NDC Lookup › RxCUI directory › RxCUI 2723657

Selumetinib 5 MG Oral Granules [Koselugo] — RxCUI 2723657

RxNorm drug concept · Semantic branded drug
RxCUI 2723657 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2723657
Official nameSelumetinib 5 MG Oral Granules [Koselugo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asKoselugo 5 MG Oral Granules
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)3,980 prescriptions · 28 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Selumetinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Koselugo targets plexiform neurofibromas — the large, deep nerve tumors that can grow in people with neurofibromatosis type 1 (NF1) when they can't be removed with surgery and are...
  • What exactly is this medication treating — and will it cure my (or my child's) NF1 tumors?
  • Most people experience some side effects — diarrhea, nausea, vomiting, and skin rashes (sometimes acne-like) are the most common. These are often manageable: for diarrhea, start an...
  • What side effects should I realistically expect, and which ones should I call the doctor about right away?
📖 Read our full Selumetinib guide →

🕸️ Concept Web — How Selumetinib 5 MG Oral Granules [Koselugo] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Selumetinib 5 MG Oral Granules [Koselugo] RxCUI 2723657

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Selumetinib 2289380
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Koselugo 2289419
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Selumetinib Oral Granules 2723652
    • Selumetinib Granule Product 2723651
    • Selumetinib Oral Product 2289415
    • Selumetinib Oral Granules [Koselugo] 2723656
    • Koselugo Granule Product 2723655
    • Koselugo Oral Product 2289422
    • Oral Granules 317690
    • Granule Product 1294708
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Selumetinib 5 MG Oral Granules SCD · 2723653
  • Selumetinib 5 MG SCDC · 2723650
  • Selumetinib Oral Granules SCDF · 2723652
  • Selumetinib Granule Product SCDG · 2723651
  • Selumetinib Oral Product SCDG · 2289415

Brand-Name Concepts

  • Selumetinib 5 MG [Koselugo] SBDC · 2723654
  • Selumetinib Oral Granules [Koselugo] SBDF · 2723656
  • Koselugo Granule Product SBDG · 2723655
  • Koselugo Oral Product SBDG · 2289422
  • Koselugo BN · 2289419

📦 FDA Products & Package NDCs

4 products · 6 package NDCs
6 package NDCs map to RxCUI 2723657 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00310-0610-28 28 CAPSULE in 1 BOTTLE (0310-0610-28) KOSELUGO AstraZeneca Pharmaceuticals LP 2021-06-11
00310-0610-60 60 CAPSULE in 1 BOTTLE (0310-0610-60) KOSELUGO AstraZeneca Pharmaceuticals LP 2020-04-16
00310-0625-28 28 CAPSULE in 1 BOTTLE (0310-0625-28) KOSELUGO AstraZeneca Pharmaceuticals LP 2021-06-11
00310-0625-60 60 CAPSULE in 1 BOTTLE (0310-0625-60) KOSELUGO AstraZeneca Pharmaceuticals LP 2020-04-16
00310-0635-60 60 GRANULE in 1 BOTTLE (0310-0635-60) KOSELUGO AstraZeneca Pharmaceuticals LP 2025-09-10
00310-0640-60 60 GRANULE in 1 BOTTLE (0310-0640-60) KOSELUGO AstraZeneca Pharmaceuticals LP 2025-09-10
Observed labelers: AstraZeneca Pharmaceuticals LP (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.